ARTAÇ, M. Et Al. 2016. Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study. CLINICAL GENITOURINARY CANCER , vol.14, no.4 .

ARTAÇ, M., COŞKUN, H. Ş., Korkmaz, L., Kocer, M., Turhal, N. S., ENGİN, H., ... Dede, I.(2016). Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study. CLINICAL GENITOURINARY CANCER , vol.14, no.4.

ARTAÇ, MEHMET Et Al. "Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study," CLINICAL GENITOURINARY CANCER , vol.14, no.4, 2016

ARTAÇ, MEHMET Et Al. "Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study." CLINICAL GENITOURINARY CANCER , vol.14, no.4, 2016

ARTAÇ, M. Et Al. (2016) . "Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study." CLINICAL GENITOURINARY CANCER , vol.14, no.4.

@article{article, author={MEHMET ARTAÇ Et Al. }, title={Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study}, journal={CLINICAL GENITOURINARY CANCER}, year=2016}